Premium
Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation
Author(s) -
Candeloro Matteo,
Es Nick,
Cantor Nathan,
Schulman Sam,
Carrier Marc,
Ageno Walter,
Aibar Jesus,
Donadini Marco Paolo,
Bavalia Roisin,
Arsenault MariePier,
Coppens Michiel,
Ferrante Noemi,
D’Addezio Andrea,
Sormani Stefano,
Porreca Ettore,
Di Nisio Marcello
Publication year - 2021
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.15476
Subject(s) - medicine , gastrointestinal bleeding , discontinuation , anticoagulant , hazard ratio , incidence (geometry) , rivaroxaban , vitamin k antagonist , lower gastrointestinal bleeding , apixaban , surgery , warfarin , confidence interval , colonoscopy , atrial fibrillation , colorectal cancer , physics , cancer , optics
Background Gastrointestinal bleeding frequently complicates anticoagulant therapy causing treatment discontinuation. Data to guide the decision regarding whether and when to resume anticoagulation based on the risks of thromboembolism and recurrent bleeding are scarce. Objectives We aimed to retrospectively evaluate the incidence of these events after anticoagulant‐related gastrointestinal bleeding and assess their relationship with timing of anticoagulation resumption. Methods Patients hospitalized because of gastrointestinal bleeding during oral anticoagulation for any indication were eligible. All patients were followed up to 2 years after the index bleeding for recurrent major or clinically relevant non‐major bleeding, venous or arterial thromboembolism, and mortality. Results We included 948 patients hospitalized for gastrointestinal bleeding occurring during treatment with vitamin K antagonists ( n = 531) or direct oral anticoagulants ( n = 417). In time‐dependent analysis, anticoagulant treatment was associated with a higher risk of recurrent clinically relevant bleeding (hazard ratio [HR] 1.55; 95% confidence interval [CI] 1.08–2.22), but lower risk of thromboembolism (HR 0.34; 95% CI 0.21–0.55), and death (HR 0.50; 95% CI 0.36–0.68). Previous bleeding, index major bleeding, and lower glomerular filtration rate were associated with a higher risk of recurrent bleeding. The incidence of recurrent bleeding increased after anticoagulation restart independently of timing of resumption. Conclusions Anticoagulant treatment after gastrointestinal bleeding is associated with a lower risk of thromboembolism and death, but higher risk of recurrent bleeding. The latter seemed to be influenced by patient characteristics and less impacted by time of anticoagulation resumption.